The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on June 24, 2025

Health 2.0 Conference Receives Positive Reviews For Its Focus On Healthcare Accessibility

Health 2.0 Conference Receives Positive Reviews For Its Focus On Healthcare Accessibility

The 3-day health event is praised for highlighting healthcare accessibility and driving innovation to make quality care more inclusive and accessible for all. DUBAI, UNITED ARAB EMIRATES, June 24, 2025 /⁨EINPresswire.com⁩/ -- The upcoming Health 2.0 …

Work-Related Burnout on the Rise: Dr. Indira Priyadarshini Urges Early Intervention

Work-Related Burnout on the Rise: Dr. Indira Priyadarshini Urges Early Intervention

Work burnout on the rise. Dr. Indira Priyadarshini urges early intervention to protect mental health and prevent long-term long-term consequences. DUBAI, DUBAI, UNITED ARAB EMIRATES, June 24, 2025 /⁨EINPresswire.com⁩/ -- With growing demands in the …

Medical Supplierz Launches New Digital Platform to Streamline Global Medical Equipment Trade

Medical Supplierz Launches New Digital Platform to Streamline Global Medical Equipment Trade

KUWAIT, KUWAIT, June 24, 2025 /⁨EINPresswire.com⁩/ -- Medical Supplierz, a B2B platform specializing in healthcare procurement, has announced the official launch of its upgraded digital marketplace, aimed at simplifying and securing international trade in …

KIF18A Inhibitor Clinical Trials FDA Approved KIF18A Targeting Therapies Market Report

KIF18A Inhibitor Clinical Trials FDA Approved KIF18A Targeting Therapies Market Report

Delhi, June 24, 2025 (GLOBE NEWSWIRE) -- Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms …

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are …

Dr. Mark Kirchhof appointed President of the Canadian Dermatology Association

Dr. Mark Kirchhof appointed President of the Canadian Dermatology Association

OTTAWA, June 24, 2025 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Mark Kirchhof as CDA President, effective June 19, 2025. Dr. Mark Kirchhof is a respected dermatologist, academic, and leader …

Le Dr Mark Kirchhof nommé président de l’Association canadienne de dermatologie

Le Dr Mark Kirchhof nommé président de l’Association canadienne de dermatologie

OTTAWA, 24 juin 2025 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) est fière d’annoncer la nomination du Dr Mark Kirchhof au poste de président de l’ACD. Il assumera ses fonctions à compter du 19 juin 2025. Le Dr Mark Kirchhof est un …

Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas

Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas

Heat-triggered release mechanism unequivocally confirmed Favorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS) One participant with …

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase 2 clinical …

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a …

Hapbee Technologies Inc. Closes 2024 with Record Q4 Device Sales, Global Distribution Partnerships and Strategic Board Appointments

Hapbee Technologies Inc. Closes 2024 with Record Q4 Device Sales, Global Distribution Partnerships and Strategic Board Appointments

Fueled by a 198% surge in Q4 device sales revenue and a 200% increase in shipments, Hapbee’s revitalized marketing strategy, expanded retail footprint, luxury spa partnerships, and high-profile Board additions have set the stage for accelerated growth …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service